Alpha Teknova Inc - Asset Resilience Ratio
Alpha Teknova Inc (TKNO) has an Asset Resilience Ratio of 14.89% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TKNO working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Alpha Teknova Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Alpha Teknova Inc.
Liquid Assets Composition Over Time
This chart breaks down Alpha Teknova Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Alpha Teknova Inc debt and liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $15.43 Million | 14.89% |
| Total Liquid Assets | $15.43 Million | 14.89% |
Asset Resilience Insights
- Moderate Liquidity: Alpha Teknova Inc has 14.89% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Alpha Teknova Inc Industry Peers by Asset Resilience Ratio
Compare Alpha Teknova Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for Alpha Teknova Inc (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Alpha Teknova Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 14.89% | $15.43 Million | $103.58 Million | -7.58pp |
| 2024-12-31 | 22.47% | $26.69 Million | $118.77 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $128.59 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $166.51 Million | -- |
| 2020-12-31 | 2.88% | $1.81 Million | $62.91 Million | -6.58pp |
| 2019-12-31 | 9.45% | $5.53 Million | $58.51 Million | -- |
About Alpha Teknova Inc
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sam… Read more